Fantappiè Ornella, Sassoli Chiara, Tani Alessia, Nosi Daniele, Marchetti Serena, Formigli Lucia, Mazzanti Roberto
Department of Experimental and Clinical Medicine - Section of Internal Medicine and Hepatology, University of Florence and Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Department of Experimental and Clinical Medicine - Section of Anatomy and Histology, University of Florence, Florence, Italy.
J Cell Mol Med. 2015 Jun;19(6):1410-7. doi: 10.1111/jcmm.12528. Epub 2015 Feb 18.
Mitochondria play a crucial role in pathways of stress conditions. They can be transported from one cell to another, bringing their features to the cell where they are transported. It has been shown in cancer cells overexpressing multidrug resistance (MDR) that mitochondria express proteins involved in drug resistance such as P-glycoprotein (P-gp), breast cancer resistant protein and multiple resistance protein-1. The MDR phenotype is associated with the constitutive expression of COX-2 and iNOS, whereas celecoxib, a specific inhibitor of COX-2 activity, reverses drug resistance of MDR cells by releasing cytochrome c from mitochondria. It is possible that COX-2 and iNOS are also expressed in mitochondria of cancer cells overexpressing the MDR phenotype. This study involved experiments using the human HCC PLC/PRF/5 cell line with and without MDR phenotype and melanoma A375 cells that do not express the MDR1 phenotype but they do iNOS. Western blot analysis, confocal immunofluorescence and immune electron microscopy showed that iNOS is localized in mitochondria of MDR1-positive cells, whereas COX-2 is not. Low and moderate concentrations of celecoxib modulate the expression of iNOS and P-gp in mitochondria of MDR cancer cells independently from inhibition of COX-2 activity. However, A375 cells that express iNOS also in mitochondria, were not MDR1 positive. In conclusion, iNOS can be localized in mitochondria of HCC cells overexpressing MDR1 phenotype, however this phenomenon appears independent from the MDR1 phenotype occurrence. The presence of iNOS in mitochondria of human HCC cells phenotype probably concurs to a more aggressive behaviour of cancer cells.
线粒体在应激条件通路中发挥着关键作用。它们可以从一个细胞运输到另一个细胞,将其特性带到被运输到的细胞中。在过表达多药耐药(MDR)的癌细胞中已表明,线粒体表达参与耐药的蛋白质,如P-糖蛋白(P-gp)、乳腺癌耐药蛋白和多耐药蛋白-1。MDR表型与COX-2和诱导型一氧化氮合酶(iNOS)的组成性表达相关,而COX-2活性的特异性抑制剂塞来昔布通过从线粒体释放细胞色素c来逆转MDR细胞的耐药性。在过表达MDR表型的癌细胞线粒体中也可能表达COX-2和iNOS。本研究涉及使用具有和不具有MDR表型的人肝癌PLC/PRF/5细胞系以及不表达MDR1表型但表达iNOS的黑色素瘤A375细胞进行实验。蛋白质免疫印迹分析、共聚焦免疫荧光和免疫电子显微镜显示,iNOS定位于MDR1阳性细胞的线粒体中,而COX-2则不然。低浓度和中等浓度的塞来昔布独立于对COX-2活性的抑制来调节MDR癌细胞线粒体中iNOS和P-gp的表达。然而,线粒体中也表达iNOS的A375细胞不是MDR1阳性。总之,iNOS可以定位于过表达MDR1表型的肝癌细胞的线粒体中,然而这种现象似乎独立于MDR1表型的出现。人肝癌细胞表型的线粒体中iNOS的存在可能促使癌细胞表现出更具侵袭性的行为。